Targeting the Pregnane X Receptor Using Microbial Metabolite Mimicry
Author:
Dvořák Zdeněk, Kopp Felix, Costello Cait M., Kemp Jazmin S., Li Hao, Vrzalová Aneta, Štěpánková Martina, Bartoňková Iveta, Jiskrová Eva, Poulíková Karolína, Vyhlídalová Barbora, Nordstroem Lars U., Karunaratne Chamini, Ranhotra Harmit, Mun Kyu Shik, Naren Anjaparavanda P., Murray Iain, Perdew Gary H., Brtko Julius, Toporova Lucia, Schon Arne, Wallace William G., Walton William G., Redinbo Matthew R., Sun Katherine, Beck Amanda, Kortagere Sandhya, Neary Michelle C., Chandran Aneesh, Vishveshwara Saraswathi, Cavalluzzi Maria M., Lentini Giovanni, Cui Julia Yue, Gu Haiwei, March John C., Chaterjee Shirshendu, Matson Adam, Wright Dennis, Flannigan Kyle L., Hirota Simon A., Sartor R. Balfour, Mani SridharORCID
Abstract
AbstractThe human pregnane X receptor (PXR), a master regulator of drug metabolism, has important roles in intestinal homeostasis and abrogating inflammation. Existing PXR ligands have substantial off-target toxicity. Based on prior work that established microbial (indole) metabolites as PXR ligands, we proposed microbial metabolite mimicry as a novel strategy for drug discovery that allows to exploit previously unexplored parts of chemical space. Here we report functionalized indole-derivatives as first-in-class non-cytotoxic PXR agonists, as a proof-of-concept for microbial metabolite mimicry. The lead compound, FKK6, binds directly to PXR protein in solution, induces PXR specific target gene expression in, cells, human organoids, and mice. FKK6 significantly represses pro-inflammatory cytokine production cells and abrogates inflammation in mice expressing the human PXR gene. The development of FKK6 demonstrates for the first time that microbial metabolite mimicry is a viable strategy for drug discovery and opens the door to mine underexploited regions of chemical space.
Publisher
Cold Spring Harbor Laboratory
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|